Posted by Michael Wonder on 01 Nov 2020
BMS appeals final appraisal document for nivolumab for non-small cell lung cancer
30 October 2020 - The appeal will be heard on 1 December 2020.
NICE has received an appeal against the Final Appraisal Document for nivolumab for patients with non-squamous, non-small cell lung cancer.
The final appraisal document relates to a Cancer Drugs Fund review of TA484.
